MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

IAVI collaborates with Serum to develop antibodies for HIV and other diseases

IAVI collaborates with Serum to develop antibodies for HIV and other diseases

Theinternational AIDS Vaccine Initiative (IAVI) has entered into a strategic partnership with Serum Institute of India in order to manufacture and develop broadly neutralizingmonoclonal antibody (bNAbs) products for HIV and help tackle other global health challenges as well. While the IAVI works with a comprehensive approach that emphasizes the need to develop AIDS and HIV prevention and treatment programs, the Serum Institute of India manufactures immunobiological drugs and vaccines in India.

Mark Feinberg, IAVI president and CEO, says that this partnership is expected to bring both the organisations to a position where they will invent a viable and sustainable pathway to manufacture antibody-based products that are affordable and accessible for all. If this works out, they also have plans to apply their innovative monoclonal antibody therapeutics to target other diseases. According to a statement made by Adar Poonawalla, CEO of Serum Institute of India, the company has a set a benchmark globally with its vaccines and pharmaceutical products, and now, it is already in the process of utilising this expertise in the antibody development space.

He mentioned, “Serum Institute and IAVI have joined forces in the fight against HIV with the aim of making cost-effective monoclonal antibodies for HIV, and in the fields of antimicrobial resistance and anti-snake venom. Provided the breadth of our technology, I am confident that we will be able to make positive contributions in these important areas.” IAVI with its partners also hopes to explore strategies by which it can directly deliver bNAbs to prevent HIV infection.

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED